|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 45.00 USD | +3.42% |
|
-4.26% | +12.50% |
| Market Cap | 49.84M 43.77M 40.71M 37.36M 70.19M 4.8B 71.27M 483M 189M 2.36B 187M 183M 8.16B | P/E 2024 |
225x | P/E 2025 | 8.64x |
|---|---|---|---|---|---|
| Enterprise Value | 57.45M 50.46M 46.93M 43.06M 80.91M 5.53B 82.16M 557M 218M 2.72B 216M 211M 9.41B | EV / Sales 2024 |
0.46x | EV / Sales 2025 | 0.24x |
| Free-Float |
17.08% | Yield 2024 * |
-
| Yield 2025 | - |
| 1 day | +3.42% | ||
| 1 week | -4.26% | ||
| 3 months | -13.01% | ||
| 6 months | +21.62% | ||
| Current year | +12.50% |
| 1 week | 42.01 |  | 45 |
| 1 month | 42.01 | | 50 |
| Current year | 37 | | 53 |
| 1 year | 21 | | 53 |
| 3 years | 21 | | 53 |
| 5 years | 15.51 | | 62 |
| 10 years | 3.05 | | 62 |
| Manager | Title | Age | Since |
|---|---|---|---|
Darren Seirer
CEO | Chief Executive Officer | 52 | 2022-12-31 |
Nathan Shandy
DFI | Director of Finance/CFO | 39 | 2025-08-01 |
| Chief Executive Officer | 52 | 2014-09-10 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 77 | 2015-11-17 | |
John Gonzalez
BRD | Director/Board Member | 76 | 2016-05-31 |
Gregory Melsen
BRD | Director/Board Member | 74 | 2018-01-01 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 6/2/26 | Buy | Director | 225 | 0.0190% | ||
| 5/28/26 | Buy | Director | 900 | 0.0759% | ||
| 5/14/26 | Buy | Director | 205 | 0.0173% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +3.42% | -4.26% | +40.62% | +66.67% | 49.84M | |
| +0.63% | -3.06% | +16.50% | -10.12% | 66.74B | |
| +1.23% | +2.80% | +38.09% | +200.66% | 53.32B | |
| +10.08% | +51.80% | +51.80% | +51.80% | 48.12B | |
| -1.32% | -7.38% | -57.37% | -56.96% | 38.25B | |
| +0.78% | -1.84% | +53.73% | -25.20% | 29.85B | |
| +0.84% | +0.36% | +67.62% | +84.46% | 23.51B | |
| -5.17% | -12.54% | +58.33% | -55.63% | 21.45B | |
| -1.21% | +1.12% | +0.90% | +164.17% | 19.97B | |
| +1.31% | +3.24% | +81.47% | +157.97% | 16.47B | |
| Average | +1.06% | -0.48% | +35.17% | +57.78% | 31.77B | |
| Weighted average by Cap. | +1.49% | +0.11% | +29.07% | +51.18% |
| 2024 | 2025 | |
|---|---|---|
| Net sales | 183M 161M 150M 137M 258M 17.64B 262M 1.78B 694M 8.67B 688M 673M 29.99B | 207M 182M 169M 155M 292M 19.98B 297M 2.01B 786M 9.82B 779M 762M 33.96B |
| Net income | 551K 484K 450K 413K 776K 53.06M 788K 5.34M 2.09M 26.09M 2.07M 2.02M 90.2M | 5.66M 4.97M 4.62M 4.24M 7.97M 545M 8.09M 54.87M 21.44M 268M 21.24M 20.78M 926M |
| Net Debt | 36.99M 32.49M 30.21M 27.72M 52.09M 3.56B 52.89M 359M 140M 1.75B 139M 136M 6.05B | 7.62M 6.69M 6.22M 5.71M 10.73M 733M 10.89M 73.87M 28.86M 361M 28.59M 27.97M 1.25B |
Employees
353
Sector
Pharmaceuticals
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-07-23 | US$42.01 | -10.62% | 110 |
- Stock Market
- Stocks
- JANL Stock
Select your edition
All financial news and data tailored to specific country editions
